Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by general360on Aug 10, 2020 12:03pm
191 Views
Post# 31387727

RE:7 other molecules sitting in limbo!

RE:7 other molecules sitting in limbo!uh, where did u get 7 other compounds from?  Why don't we try TWENTY! 20.  the BIG TWO-OH.

where did i get my number from? i got it from MYSELF! haha, actually, DIRECTLY FROM DM HIS BAD AZZ SELF!!!

the transcript from 2018 AGM Q&A:

Here's the relevant excerpt, and we've talked about this yeah, before:

New compounds:  actually, it was discussed very briefly at the AGM during the Q&A.  See my notes

DM mentioed there are 20 more "ready to go". 

Q- you mention that this is your lead drug, which implies there are others behind it….
A - there are 20 more ready to go. Emily has done an incredible job getting this ready to go.  so when we say there’s 20 more, dont think we can turn the car key and the car goes. these have been designed for different reasons. so you have brd2, brd3, brd4 and brdT for testes, each has a bd1 and a bd2, so we can target various places in , we have pan inhibitors that hit them all, we have bd2 selective, we have ones we think will be great in autoimmune, but there are 20 that really have some very exciting properties, we think we can move forward with partnerships with other companies. the reason we believe that is once this data comes out, if its even close to what we're expecting, we're going to have a long line up of people who want to partner in BET/bromodomain because this is really a change in how medicine is made



Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp?postid=28641927#PGOqytRq2uIhMDe6.99
<< Previous
Bullboard Posts
Next >>